Retatrutide vs Semaglutide: How Does the New Triple Agonist Compare?

Semaglutide, the active ingredient in Ozempic and Wegovy, is a GLP-1 receptor agonist — it mimics a gut hormone called glucagon-like peptide-1 that slows digestion, increases feelings of fullness, and reduces appetite. Retatrutide takes that same GLP-1 activity and adds two more hormone targets: the GIP receptor (also targeted by tirzepatide, the drug in Mounjaro and Zepbound) and, uniquely, the glucagon receptor.

Glucagon is usually thought of as insulin's opposite — it raises blood sugar — but at the doses used in retatrutide, activating the glucagon receptor appears to increase energy expenditure and fat oxidation, essentially helping the body burn more calories rather than only eating fewer of them. This "triple agonist" mechanism is why retatrutide has been nicknamed a possible next step beyond tirzepatide, which itself outperformed semaglutide in head-to-head trials. Eli Lilly, which developed both tirzepatide and retatrutide, has been explicit that combining appetite suppression with increased energy expenditure is the rationale for chasing even greater weight loss than currently approved medications provide.

Retatrutide's phase 2 trial, led by Dr. Ania Jastreboff and published in the *New England Journal of Medicine* in 2023, tested doses up to 12mg weekly in adults with obesity. At 24 weeks, the highest dose group had lost an average of 17.5% of body weight. By 48 weeks, that number had climbed to 24.2%, compared with about 2.1% in the placebo group — and the weight-loss curve had not clearly flattened, suggesting further loss was likely with continued treatment.

Those phase 2 numbers were confirmed and extended in retatrutide's first phase 3 trial, TRIUMPH-1, with results reported in 2026. Over 80 weeks, participants on the 12mg dose lost an average of 28.3% of their body weight — roughly 70 pounds for the average participant in the trial. That places retatrutide's early results well above what's been reported for any currently approved GLP-1 medication, including tirzepatide, though it's worth remembering that longer trial duration (80 weeks vs. 48 or 68 weeks for other drugs) is part of why the number looks larger.

Semaglutide's pivotal trial, STEP 1 (Wilding et al., NEJM, 2021), found that adults with obesity taking 2.4mg of semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared with about 2.4% on placebo. That was, at the time, a dramatic improvement over older weight-loss medications, and it's still the number most people mean when they talk about semaglutide's effectiveness.

Lined up side by side, retatrutide's phase 2 and phase 3 results are noticeably larger — nearly double semaglutide's average percentage in some comparisons. But this is a cross-trial comparison, not a head-to-head study where the same protocol, population, and follow-up period were used for both drugs. Differences in trial length, participant characteristics, and dose-titration schedules can all inflate or shrink an apparent gap between drugs tested in separate trials. A true head-to-head trial between retatrutide and semaglutide (or tirzepatide) would give a much more reliable answer, and until one is published, the honest takeaway is "retatrutide looks more effective in early data" rather than "retatrutide is proven to beat semaglutide."

Not for routine prescribing. As of fall 2026, retatrutide has not received FDA approval and is not commercially available outside of clinical trials. Lilly has reported positive topline results from TRIUMPH-1, its first phase 3 trial, and additional TRIUMPH trials are underway or reporting results, but a full regulatory submission and review process still needs to play out before it could reach pharmacies.

That timeline matters practically: if you're choosing a treatment today, retatrutide isn't one of the options on the table, no matter how promising its trial data looks. Semaglutide and tirzepatide remain the approved, available GLP-1-class medications, and switching to retatrutide later — if and when it's approved — is generally straightforward for people already established on a related medication, similar to how people currently switch between semaglutide and tirzepatide.

Retatrutide's side-effect profile in trials looks broadly similar to semaglutide and tirzepatide — nausea, diarrhea, constipation, and vomiting were the most common complaints, particularly during dose escalation. Because retatrutide adds a third hormone pathway, there was some concern that side effects might be worse, but phase 2 and phase 3 data so far haven't shown a dramatically higher discontinuation rate compared with tirzepatide trials.

One notable signal from early retatrutide trials was a modest increase in heart rate at higher doses, which researchers are continuing to monitor in ongoing phase 3 work — a reminder that a drug's full safety picture only becomes clear after longer trials and, eventually, years of real-world use. Semaglutide, by contrast, now has roughly a decade of use in diabetes (as Ozempic) and several years in obesity treatment (as Wegovy), giving prescribers a much deeper safety track record to draw on today.

For most people, no. Retatrutide's trial results are genuinely exciting, but "promising and unapproved" is a very different category from "available and proven." Delaying treatment for a medical condition — including obesity and its related health risks — to wait for a drug with no confirmed approval date isn't generally advisable, especially since semaglutide and tirzepatide are already delivering substantial, well-documented results for most people who use them.

If you're currently on semaglutide and considering your options, a more useful conversation with your prescriber is whether tirzepatide — already approved and shown to outperform semaglutide in the head-to-head SURMOUNT-5 trial — might be a better fit for you right now, rather than waiting on a drug that isn't yet available. Retatrutide is worth watching, and Lea will keep this page updated as its approval status changes, but it shouldn't be the deciding factor in your treatment plan today.